



*healthcare*



Perspective

---

# Reframing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients

---

Priya Agarwal and Kenneth J. Friedman

## Topic Collection

Why Some Patients Never Fully Recover: Post Active Phase of Infection Syndromes (PAPIS)

Edited by

Kenneth J. Friedman, Patricia A. Fennell, Evan Spivack, James M. Oleske, Nancy Klimas, Prof. Dr. Pawel Zalewski and Susan M. Levine



<https://doi.org/10.3390/healthcare13151917>

Perspective

# Reframing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients

Priya Agarwal <sup>1</sup>  and Kenneth J. Friedman <sup>2,\*</sup> 

<sup>1</sup> Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA; pa399@rwjms.rutgers.edu

<sup>2</sup> Department of Medicine, Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ 08084, USA

\* Correspondence: kenneth.j.friedman@gmail.com

## Abstract

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a worldwide challenge. There are an estimated 17–24 million patients worldwide, with an estimated 60 percent or more who have not been diagnosed. Without a known cure, no specific curative medication, disability lasting years to being life-long, and disagreement among healthcare providers as to how to most appropriately treat these patients, ME/CFS patients are in need of assistance. Appropriate healthcare provider education would increase the percentage of patients diagnosed and treated; however, in-school healthcare provider education is limited. To address the latter issue, the New Jersey Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Association (NJME/CFSA) has developed an independent, incentive-driven, learning program for students of the health professions. NJME/CFSA offers a yearly scholarship program in which applicants write a scholarly paper on an ME/CFS-related topic. The efficacy of the program is demonstrated by the 2024–2025 first place scholarship winner's essay, which addresses the biological basis of ME/CFS and how the healthcare provider can improve the quality of life of ME/CFS patients. For the reader, the essay provides an update on what is known regarding the biological underpinnings of ME/CFS, as well as a medical student's perspective as to how the clinician can provide care and support for ME/CFS patients. The original essay has been slightly modified to demonstrate that ME/CFS is a worldwide problem and for publication.

**Keywords:** myalgic encephalomyelitis; chronic fatigue syndrome; chronic illness; patient-centered care; advocacy



Academic Editors: Ken Inoue and Raphael B. Stricker

Received: 17 May 2025

Revised: 31 July 2025

Accepted: 1 August 2025

Published: 5 August 2025

**Citation:** Agarwal, P.; Friedman, K.J. Reframing Myalgic

Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients. *Healthcare* **2025**, *13*, 1917. <https://doi.org/10.3390/healthcare13151917>

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Background

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) represents a significant worldwide healthcare challenge due to its debilitating effect on patients and the global lack of understanding of its causes and treatment. The CDC estimates that the worldwide number of individuals afflicted with ME/CFS is somewhere between 17 and 24 million [1]. While data concerning the number of patients with ME/CFS who have been properly diagnosed worldwide is scarce, the weighted average of are cent European survey suggests that an average of 60 percent of ME/CFS patients remain undiagnosed across Europe [2]. In the United States, ME/CFS is estimated to impact 836,000 to 2.5 million people with fewer than 20% of patients having received a formal diagnosis [3,4]. Thus, despite recent advancements in our understanding of the biological basis of ME/CFS, the disease remains

misunderstood, with many healthcare providers attributing its origins to psychological causes, further adding to the challenges faced by patients. Educating healthcare providers, who could then provide tailored, supportive therapies and self-help recommendations to their patients, as well as advocate for the reduction in systemic barriers to care, would greatly improve the quality of life for ME/CFS patients.

The New Jersey Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Association is working to raise healthcare-provider awareness about ME/CFS and to combat the stigma still associated with the disease. The organization actively recruits students of the healthcare professions to teach themselves about ME/CFS by offering a guided, independent study: students of the health professions who wish to become the organization's Medical Scholar Of The Year are asked to write a scholarly paper on a specific topic concerning ME/CFS and the author of the essay judged to be the most scholarly receives a partial tuition remission. The 2024–2025 question to be addressed was to review the evidence supporting the pathophysiological basis of ME/CFS and to suggest methods by which healthcare providers can support their patients' efforts in improving the quality of their lives. The essay below was written in response to that question, with the hope of raising greater awareness of this global healthcare challenge. Minor changes have been made for publication and in accordance with peer reviewer recommendations.

## 2. Introduction

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), formerly referred to as chronic fatigue syndrome (CFS), is a chronic, debilitating condition characterized by profound fatigue that does not improve with rest. Aside from extreme exhaustion, individuals with ME/CFS may experience a range of other symptoms, including post-exertional malaise, cognitive difficulties (commonly called "brain fog"), muscle and joint pain, sleep disturbances, heightened sensitivity to stimuli, flu-like symptoms, and tremors [3]. Other frequently encountered symptoms are lightheadedness and difficulty remaining upright without provoking symptoms [5]. In addition, decreased cerebral blood flow may contribute to symptoms in as many as 90 percent of adults with ME/CFS [6]. Mental health conditions such as depression and anxiety are also common, and ME/CFS patients notably have a greater risk of suicide compared to the general population [3,7].

There is wide overlap of the symptoms found in ME/CFS with those of some other chronic illnesses triggered by infection confounding the diagnosis of ME/CFS. Post-treatment Lyme disease (also known as chronic Lyme disease) and Long COVID both exhibit symptoms with profound overlap of symptoms to those of ME/CFS. The differences between ME/CFS and co-morbid conditions have been reviewed [8]. Currently, there are no biomarkers or clinical tests for ME/CFS and; therefore, its diagnosis is a diagnosis of exclusion as indicated in the Institute of Medicine report of 2015 [5]. The healthcare provider is, therefore, obligated to rule out the diagnoses of both post-treatment Lyme disease, and Long COVID. Our current understanding of the pathophysiological mechanisms producing Lyme disease and the subsequent chronic Lyme disease as well as our current understanding of the pathophysiological mechanisms involved in Long COVID have been recently reviewed in other analyses [9,10].

The United States has produced the highest number of ME/CFS research publications, approximately 8000, with the United Kingdom having produced under 6000 articles. The United States has produced 37 of the most frequently cited top 100 articles, whereas the United Kingdom has produced 32. For this reason, this paper focuses mainly on data derived from U.S. studies. Although ME/CFS impacts an estimated 836,000 to 2.5 million people in the United States, fewer than 20% of patients have received a formal diagnosis from a healthcare provider [3,4].

An additional argument for more aggressive treatment of ME/CFS and its impression is the economic impact of the disease. To our knowledge, the worldwide economic impact of the disease has not been calculated. National Health and Nutrition Examination Survey (NHANES) data from 2021 to 2022 suggest that 1.3% of U.S. adults may have contracted ME/CFS with an ensuing economic cost of approximating \$51 billion annually [11]. A second estimate of total annual direct and indirect cost of ME/CFS is \$24 billion in the United States [12]. An ever-increasing number of long COVID patients, with many symptoms in common with ME/CFS, provide additional incentives for healthcare providers to learn how to treat these symptoms and manage these patients.

Women are disproportionately affected, with some studies reporting a female-to-male ratio as high as 4:1 [3,4]. The burden of ME/CFS is immense and significantly impacts patients' quality of life, often leaving them unable to work, pursue education, or engage in activities that previously brought them joy. It is estimated that only about 5% of ME/CFS patients are able to achieve a full recovery and return to their prior state of health [13,14].

ME/CFS patients often face stigma in the healthcare world. Many healthcare providers and researchers have historically dismissed ME/CFS as psychological, or met patients with a lack of understanding and/or disbelief [15]. This mindset invalidated, and in some cases continues to invalidate, the struggle of patients, while also delaying the development of effective treatments. Recent advances in research, however, have uncovered various biochemical and physiological abnormalities associated with ME/CFS, challenging these notions [3].

In addition to the physical challenges, the mental health burden on patients is profound. Stigma, lack of understanding, and limited treatment options only further exacerbate the challenges faced by ME/CFS patients. Here we review the literature supporting the biological basis of ME/CFS and provide actionable recommendations for healthcare providers which will alleviate the physical and mental health burdens faced by patients. In so doing, we hope to draw awareness to ME/CFS and promote compassionate, effective care for affected patients.

### **3. Part 1: Challenging Psychological/Psychiatric Causation of Disease**

#### *3.1. Overview of Biological and Physiological Characteristics of Disease*

Currently, ME/CFS does not have a definitive confirmatory test, and is therefore largely a diagnosis of exclusion, often subjecting patients to months and years of symptoms without diagnosis or treatment [13]. Recent research has highlighted the biological basis of ME/CFS, offering avenues for timely diagnosis and development of therapeutics. These advances have helped to validate patient experiences, reduce stigma, and offer hope for earlier diagnosis and development of targeted therapies. These findings also serve to challenge outdated perceptions of ME/CFS as a psychosomatic condition by highlighting its complex, multi-systemic nature. A sampling of some of these recent research findings which underscore the biological and pathological basis of ME/CFS are provided in Appendix A.

ME/CFS onset often follows viral infection, such as COVID-19 or Epstein–Barr virus, though some patients may not have a defined triggering event [13]. The disease has been demonstrated to have a genetic susceptibility, with multiple twin concordance studies demonstrating higher rates of disease in monozygotic twins than dizygotic twins, indicating that certain patients may be at higher risk of disease development depending on their family history [13,16–18]. Specifically, three genes, including *IL8*, *NFKBIA* and *TNFAIP3*, have been identified as upregulated in ME/CFS patients [19]. All three of these genes are related to inflammation, circadian clock function, metabolic dysregulation, cellular stress responses, and mitochondrial function, implying that their upregulation could be contributing to the symptomatology of ME/CFS through the disruption of normal physiologic processes [19].

The possibility that altered gene function is associated with ME/CFS is also supported by the frequent co-occurrence of Ehlers-Danlos Syndrome (EDS) and ME/CFS, particularly the joint hypermobility subtype [20,21]. While further studies with larger cohorts of patients are required to confirm these patterns, the developing understanding of potentially altered genes and/or gene expression in ME/CFS patients can begin to pave the way for future research into targeted therapy, such as the use of gene editing.

Immunologic biomarkers of ME/CFS have also been identified. Patients are noted to have increased levels of inflammatory mediators such as pro-inflammatory cytokines, which likely contribute to fatigue and autonomic symptoms [22]. Additionally, ME/CFS patients have been found to have a reduced T-helper ( $T_H$ )1 response, with an overactive  $T_H$ 2 response, as indicated by increased levels of interleukin(IL)-10 and a decreased interferon (IFN)- $\gamma$ /IL-10 ratio, resulting in suppressed cellular immune function with persistent low-grade inflammation [22–24]. Therefore, a skewed  $T_H$ 1/ $T_H$ 2 balance, and the presence of elevated pro-inflammatory mediators such as TNF- $\alpha$ , IL-1, PMN-elastase, lysozyme, and serum neopterin, may point toward a diagnosis of ME/CFS with consideration of the patient's presentation and clinical picture [22]. Recently, biologics such as monoclonal antibodies are being leveraged in the treatment of chronic illnesses, such as systemic lupus erythematosus and inflammatory bowel disease. As research continues to emerge about immune dysregulation in ME/CFS patients, similar treatment strategies may be able to be explored, though further research is required to confirm safety and efficacy.

Furthermore, neuroanatomical and physiological abnormalities have been noted in ME/CFS patients. Magnetic Resonance Imaging (MRI) has found reductions in the volume of both brain white and gray matter in ME/CFS patients, with the degree of reduction correlating to symptom severity in some patients [22,25,26]. These findings, however, are not necessarily specific to ME/CFS and therefore warrant further exploration. Some patients have also been found to have impairments in brain blood perfusion, as determined by Positron emission tomography (PET); however, these findings are not universal among all patients [22,27]. Furthermore, episodic alterations in brain blood perfusion is demonstrated by an approximate four-fold decrease in internal carotid and vertebral artery blood flow upon patients going from supine to head tilt in comparison to healthy controls using extra cranial Doppler [6]. Blood oxygen level dependent functional MRI (BOLD fMRI) and electroencephalogram (EEG), have uncovered functional differences between ME/CFS patients as compared to healthy controls, with noted increases in brain activity and disrupted brain waves during sleep, further suggesting neurological abnormalities may be contributing to the progression of disease [22,28,29]. These neurological changes could be leveraged by providers as part of diagnostic criteria for ME/CFS, along with other supporting factors from the patient's history and presentation.

These genetic, immunologic, and neurologic findings highlight the multi-factorial nature of ME/CFS. These discoveries offer avenues for better diagnostic criteria and, therefore, earlier diagnosis. Given how much is still unknown, there is an urgent need for continued research so that targeted therapies can be developed that address the underlying biological mechanisms of ME/CFS.

### *3.2. Countering the Psychological Cause Theory*

Though ME/CFS has been classified as a neurological disease by the World Health Organization (WHO) since 1969, many people, including many healthcare providers, still believe it to be a psychosomatic condition [30]. This mindset is ill-informed and neglects decades of research that demonstrate the biological basis of this disease with immunologic, hematologic, and neurologic dysfunction. Additionally, a prospective study of individuals with mononucleosis found that those who progressed to develop ME/CFS exhibited greater

physical symptoms and immune abnormalities, but no increase in psychological symptoms, compared to those who recovered [31].

Attributing poorly understood diseases to psychological causes is neither a new nor uncommon occurrence within the medical community. This has been the case for diseases such as rheumatoid arthritis, asthma, fibromyalgia, irritable bowel syndrome, and endometriosis [30]. This historical pattern is notably pronounced for diseases that disproportionately affect women, as seen in the case of ME/CFS, given that the concerns of women are frequently dismissed [30].

## 4. Part 2: Recommendations for Healthcare Providers to Reduce Stigma

### 4.1. Mental Health Burden of Disease

The profound physical fatigue and associated symptoms of ME/CFS lead to a significant mental health burden for affected patients. One study of 169 patients found that a majority (90.5%) felt that there was a lack of understanding of their disease, prompting them to feel uncomfortable sharing their feelings about their condition due to disbelief and trivialization from others [32]. This study also found that 88.2% of patients reported mental distress due to their condition, leading to sadness (71%), hopelessness (66.9%), and thoughts of suicide (39.3%) [32]. The main factors associated with negative mental health were the lack of a cure, feelings of social isolation, and functional limitations [32]. Suicidal thoughts in particular were prompted by being told their condition was psychological (89.5%), lacking strength (80.7%), and feeling misunderstood (80.7%) [32]. These findings demonstrate that ME/CFS is a major public health concern that deserves attention and discussion, in order to promote patient health and well-being. Providers must be aware of both the physical and mental burden of ME/CFS in order to provide effective and compassionate care, particularly with consideration that many patients feel misunderstood or dismissed by their physicians. Such an experience can be isolating and therefore requires nuanced care.

### 4.2. Recommendations for Providers

In order for providers to effectively care for patients with ME/CFS, there must first and foremost be adequate training and education programs in place that emphasize the biological basis of this disease. The U.S. Centers for Disease Control and Prevention (CDC) reports that ME/CFS is not a part of most medical school curricula, unlike other chronic diseases [33]. Therefore, many healthcare providers may be unaware of this disease and therefore may be ill-equipped to care for ME/CFS patients. Early introduction of ME/CFS as a part of the pre-clerkship curricula of medical, physician assistant, and nursing schools would be ideal and would greatly raise provider awareness of the condition, potentially reducing misdiagnoses of patients and connecting them with resources early-on in their disease course. Changing medical school curricula, however, can be challenging and time-consuming. Therefore, a more manageable action item would be to incorporate education about ME/CFS as continuing medical education (CME) lectures throughout residency and beyond, so that current and future physicians are equipped to recognize the condition and remain up to date regarding the newest developments. Education should emphasize research supporting the biological basis of disease, as well as emphasize the mental health burden that patients may face so that providers can screen for troublesome signs such as suicidality.

When it comes to caring for patients, providers must offer compassionate, evidence-based counseling, with recommendations for helpful resources for symptom management, education, and mental healthcare. Providers need to be aware that ME/CFS patients generally require longer office visits than most other patients. An analysis of U.S. healthcare

data found that ME/CFS-related appointments lasted ~23.6 min in comparison to ~19.4 min for other visits [34]. Providers may wish to consider end-of-day appointments for ME/CFS patients to ensure sufficient time. While reimbursement mechanisms that support longer, more resource-intensive provider visits for patients with complex, chronic illnesses are beginning to appear (e.g., HCPCS Add-On Code G2211- Add-on for complex longitudinal visits, CPT 99490/99439-Monthly non-face-to-face coordination, and 99487/99489-Complex CCM), healthcare providers should be encouraged to advocate for adequate compensation by influencing federal and payer-level reimbursement policies. Traditional, professional avenues of advocacy for change in healthcare are through national and specialty-specific associations, contributing to position papers, letters of comment, and testimonials to both CMS and Congress, and partnering with disease-specific (in this case ME/CFS-specific) advocacy organizations whose missions include raising awareness among lawmakers and insurers about the unmet healthcare needs of their constituency. More healthcare providers might be willing to accept patients with complex, chronic illness were the time required to manage these patients adequately compensated.

Providers can encourage patient self-education by directing patients to the CDC's ME/CFS page, which offers comprehensive information on symptoms, management strategies, and printable handouts [35].

Similarly, the Solve ME/CFS Initiative is a great resource for patients that provides webinars, patient stories, and updates on current research. Additionally, providers can recommend participation in support groups, such as those hosted by the ME Action Network or other online communities. Patients may find strength in connecting with others who share their experiences, reducing feelings of isolation and stigma.

In terms of symptom management, physicians should introduce exertional pacing strategies that teach patients how to manage their limited energy to avoid post-exertional malaise [36]. Apps such as Visible can also help patients identify triggers, manage energy levels, and monitor their progress overtime [37]. Additionally, providers should ensure that patients are regularly screened for mental health concerns. Physicians can specifically recommend therapists with experience in chronic illness and recommend simple tools for mindfulness, such as the Calm or the Headspace app, to support stress management and improve sleep quality [38,39].

Additionally, providers can suggest practical resources to improve patients' activities of daily living, such as mobility assistive devices, home modifications (e.g., in-shower benches, stair lifts, etc.), and/or physical therapy. Some patients may also benefit from dietary counseling by a dietitian, with recommendations for foods and supplements that target inflammation and optimize energy levels. Finally, patients should be informed about opportunities to participate in ongoing research/clinical trials should they be available through local organizations, as these may afford them access to innovative treatments while also offering an opportunity to directly participate in enhancing the world's understanding of ME/CFS. By offering numerous avenues for support, providers can empower patients and improve their quality of life as they navigate life with ME/CFS.

With recognition of the barriers to care that ME/CFS patients may face, providers should also strive to ensure equitable and accessible care for all. Whenever possible, physicians should offer opportunities for telemedicine visits, particularly for patients who may find it difficult to come to an office in person due to their symptoms. Offices should be accessibly designed, so that patients who may require assistive mobility devices can navigate without difficulty, as well. Taking steps such as these reduces potential barriers to care and helps ensure that patients are receiving the healthcare they deserve.

Ultimately, healthcare providers play a big role in the journey of an ME/CFS patient. Through education, tailored supportive recommendations for patients and reduction in

systemic barriers to care, physicians can greatly improve the quality of life for patients experiencing ME/CFS.

Physicians should prioritize genuinely listening to their patients' concerns, fostering trust and understanding. While physicians may not have all the answers, as much remains unknown about ME/CFS, it is essential for physicians to make every effort to connect patients with appropriate resources and support that can address their needs.

## 5. Conclusions

ME/CFS is a multi-system, chronic disease that profoundly impacts the daily lives of patients. Despite significant research advancements in understanding the biological basis of ME/CFS, it has long been misunderstood, with many attributing its origins to psychological causes, further adding to the challenges faced by patients. ME/CFS imparts a significant mental health burden on patients, leading to increased rates of depression, anxiety, and suicide [7].

Studies have demonstrated that patients with ME/CFS have alterations in genes associated with inflammation, metabolic regulation, and mitochondrial function, alongside irregularities in immune pathways marked by increased pro-inflammatory activity [13,19,22]. Neuroimaging studies have further demonstrated reductions in white and gray matter, as well as decreased brain perfusion [22]. These studies taken together illustrate the cascade of biological alterations in ME/CFS patients, strongly contradicting the notion that ME/CFS is merely a psychological disorder.

With recognition of the potentially devastating impact ME/CFS can have on the lives of patients and their families, healthcare providers have an obligation to be well-prepared to provide effective and compassionate care. Medical education and continuing professional development must prioritize teaching the biological underpinnings of ME/CFS, along with effective strategies to support patients. Providers can support patients by offering a plethora of resources including support groups, mental health services, and mobility aids. Physicians must also make efforts to reduce barriers to care, such as by offering telemedicine visits and accessible offices. Through these strategies, physicians can cultivate trust and improve the quality of life for patients with ME/CFS.

Ultimately, by addressing the biological complexities of ME/CFS, challenging outdated misconceptions, and fostering a supportive healthcare environment, we can pave the way for better outcomes and a brighter future for those living with ME/CFS.

**Author Contributions:** The topic of this article was created by K.J.F. and approved by the NJME/CFSA. The original research and content of the article was produced by P.A. The original content was modified by K.J.F. and approved by P.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** The original article was submitted by P.A. to NJME/CFSA as was an award-winning essay resulting in a \$5000 tuition remission of her medical school education. In essence, the tuition remission is the source of funding for the production of this manuscript. For submission to the journal Healthcare, and, in particular, to the PAPIS Topical Collection. The APC was funded with APC credits earned by K.J.F. for reviewing other manuscripts for MDPI.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Any additional inquiries concerning the data presented in this manuscript may be directed to K.J.F., the corresponding author.

**Acknowledgments:** The authors gratefully acknowledge the support of the NJME/CFSA—a not-for-profit patient advocate group which relies solely upon voluntary donation to fund patient assistance

and healthcare provider educational programs. We also acknowledge the support of the NJME/CFSA Medical Scholar Program whose supplemental educational program for students of the Health Professions resulted in the authoring of this manuscript.

**Conflicts of Interest:** K.J.F., as Chair of the NJME/CFSA Medical Scholar Program initially proposed the design of this study to the Medical Scholarship Committee of NJME/CFSA. As an eligible applicant for the scholarship, P.A. wrote the initial draft of the manuscript which resulted in her winning a \$5000 tuition remission credited to her tuition account at the medical school she attends.

## Appendix A. Recent Studies Underscoring the Biological Basis of ME/CFS

Citation	Description of Research
Walitt et al. [40]	<p>Brain and Nervous System Abnormalities</p> <ul style="list-style-type: none"> <li>NIH Study on Brain and Immune System Dysregulation (2024): An in-depth study by the National Institutes of Health identified abnormalities in brain regions such as the temporal-parietal junction and motor cortex in ME/CFS patients. Functional MRI scans revealed altered activity in these areas, suggesting a neurological basis for the fatigue experienced by patients. Additionally, immune system irregularities were observed, indicating a potential link between immune activation and brain function disruptions.</li> </ul>
Eaton-Fitch et al. [41]	<p>Immune System Dysregulation</p> <ul style="list-style-type: none"> <li>Researchers at Griffith University conducted a study analyzing immune gene expression in ME/CFS and Long COVID patients. The findings highlighted a state of immune exhaustion characterized by down-regulated interferon signaling and immunoglobulin genes in ME/CFS patients. This suggests a suppressed immune response, which may contribute to the chronic nature of the disease.</li> </ul>
National Institutes of Health [42]	<p>Metabolic and Mitochondrial Dysfunction</p> <ul style="list-style-type: none"> <li>The study found significant metabolic alterations in the peripheral blood mononuclear cells of ME/CFS patients. These changes included decreased glycolysis, reduced mitochondrial respiration, and impaired fatty acid oxidation, indicating a disruption in cellular energy production mechanisms.</li> </ul>
Xiong et al. [43]	<p>Gut Microbiome Imbalances</p> <ul style="list-style-type: none"> <li>The gut microbiome of ME/CFS patients was found to have distinct differences in microbial and metabolic pathways compared to healthy individuals. Notably, a reduction in butyrate-producing bacteria was observed, which may impact intestinal health and systemic inflammation.</li> </ul>
Maksoud et al. [44]	<p>An evaluation of studies of potential biomarkers for ME/CFS found consistent alterations of amino acid metabolism, mitochondrial function, and altered oxidative stress markers in patients, suggesting these could serve as potential diagnostic indicators.</p>
Rowe et al. [21] Hakim et al. [45] National Institutes of Health [42]	<p>Study finds a higher occurrence of Ehlers-Danlos Syndrome (EDS), particularly joint hypermobility, with ME/CFS</p> <ul style="list-style-type: none"> <li>Joint hypermobility is found to be significantly more common in adolescents with chronic fatigue than in controls.</li> <li>Patients with Ehlers-Danlos syndrome—Hypermobile type often met criteria for CFS.</li> <li>12–19% of ME/CFS patients may have EDS, and 50–81% show hypermobility—indicating significant comorbidity.</li> </ul>
Van Campen et al. [6]	<p>Episodic Reduction in Cerebral Blood Flow With Head Tilt</p> <ul style="list-style-type: none"> <li>About 90% of ME/CFS patients showed abnormal cerebral blood flow reduction during tilt testing, even in the absence of traditional heart rate or blood pressure abnormalities, suggesting orthostatic intolerance as a contributor to the pathophysiology of ME/CFS.</li> </ul>

## References

1. Lim, E.J.; Ahn, Y.C.; Jang, E.S.; Lee, S.W.; Lee, S.H.; Son, C.G. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J. Transl. Med.* **2020**, *18*, 100. [\[CrossRef\]](#)
2. Cullinan, J.; Pheby, D.F.H.; Araja, D.; Berkis, U.; Brenna, E.; de Korwin, J.D.; Gitto, L.; Hughes, D.A.; Hunter, R.M.; Trepel, D.; et al. Perceptions of European ME/CFS Experts Concerning Knowledge and Understanding of ME/CFS among Primary Care Physicians in Europe: A Report from the European ME/CFS Research Network (EUROMENE). *Medicina* **2021**, *57*, 208. [\[CrossRef\]](#)
3. Graves, B.S.; Patel, M.; Newgent, H.; Parvathy, G.; Nasri, A.; Moxam, J.; Gill, G.S.; Sawhney, V.; Gupta, M. Chronic Fatigue Syndrome: Diagnosis, Treatment, and Future Direction. *Cureus* **2024**, *16*, e70616. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Sandler, C.X.; Lloyd, A.R. Chronic fatigue syndrome: Progress and possibilities. *Med. J. Aust.* **2020**, *212*, 428–433. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations, Institute of Medicine. The National Academies Collection: Reports funded by National Institutes of Health. In *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness*; National Academies Press (US): Washington, DC, USA, 2015. [\[CrossRef\]](#)
6. van Campen, C.; Verheugt, F.W.A.; Rowe, P.C.; Visser, F.C. Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography. *Clin. Neurophysiol. Pract.* **2020**, *5*, 50–58. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Chu, L.; Elliott, M.; Stein, E.; Jason, L.A. Identifying and Managing Suicidality in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Healthcare* **2021**, *9*, 629. [\[CrossRef\]](#)
8. Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.; Gottschalk, G.; March, D. Chronic fatigue syndrome and co-morbid and consequent conditions: Evidence from a multi-site clinical epidemiology study. *Fatigue Biomed. Health Behav.* **2015**, *3*, 1–15. [\[CrossRef\]](#)
9. Strnad, M.; Rudenko, N.; Rego, R.O.M. Pathogenicity and virulence of *Borrelia burgdorferi*. *Virulence* **2023**, *14*, 2265015. [\[CrossRef\]](#)
10. Greenhalgh, T.; Sivan, M.; Perlowski, A.; Nikolich, J. Long COVID: A clinical update. *Lancet* **2024**, *404*, 707–724. [\[CrossRef\]](#)
11. Vahratian, A.; Lin, J.S.; Bertolli, J.; Unger, E.R. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022. *NCHS Data Brief* **2023**, *488*, 1–8.
12. Jason, L.A.; Benton, M.C.; Valentine, L.; Johnson, A.; Torres-Harding, S. The economic impact of ME/CFS: Individual and societal costs. *Dyn. Med.* **2008**, *7*, 6. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Sweetman, E.; Noble, A.; Edgar, C.; Mackay, A.; Helliwell, A.; Vallings, R.; Ryan, M.; Tate, W. Current Research Provides Insight into the Biological Basis and Diagnostic Potential for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *Diagnostics* **2019**, *9*, 73. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Cairns, R.; Hotopf, M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occup. Med.* **2005**, *55*, 20–31. [\[CrossRef\]](#) [\[PubMed\]](#)
15. McManimen, S.; McClellan, D.; Stoothoff, J.; Gleason, K.; Jason, L.A. Dismissing chronic illness: A qualitative analysis of negative health care experiences. *Health Care Women Int.* **2019**, *40*, 241–258. [\[CrossRef\]](#)
16. Buchwald, D.; Herrell, R.; Ashton, S.; Belcourt, M.; Schmalings, K.; Sullivan, P.; Neale, M.; Goldberg, J. A twin study of chronic fatigue. *Psychosom. Med.* **2001**, *63*, 936–943. [\[CrossRef\]](#)
17. Sabath, D.E.; Barcy, S.; Koelle, D.M.; Zeh, J.; Ashton, S.; Buchwald, D. Cellular immunity in monozygotic twins discordant for chronic fatigue syndrome. *J. Infect. Dis.* **2002**, *185*, 828–832. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Sullivan, P.F.; Evengård, B.; Jacks, A.; Pedersen, N.L. Twin analyses of chronic fatigue in a Swedish national sample. *Psychol. Med.* **2005**, *35*, 1327–1336. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Sweetman, E.; Ryan, M.; Edgar, C.; MacKay, A.; Vallings, R.; Tate, W. Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis/chronic fatigue syndrome. *Int. J. Immunopathol. Pharmacol.* **2019**, *33*, 2058738418820402. [\[CrossRef\]](#)
20. Castori, M.; Morlino, S.; Celletti, C.; Ghibellini, G.; Bruschini, M.; Grammatico, P.; Blundo, C.; Camerota, F. Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. *Am. J. Med. Genet. A* **2013**, *161*, 2989–3004. [\[CrossRef\]](#)
21. Rowe, P.C.; Barron, D.F.; Calkins, H.; Maumenee, I.H.; Tong, P.Y.; Geraghty, M.T. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. *J. Pediatr.* **1999**, *135*, 494–499. [\[CrossRef\]](#)
22. Fischer, D.B.; William, A.H.; Strauss, A.C.; Unger, E.R.; Jason, L.; Marshall, G.D., Jr.; Dimitrakoff, J.D. Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers. *Fatigue* **2014**, *2*, 93–109. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Broderick, G.; Fuite, J.; Kreitz, A.; Vernon, S.D.; Klimas, N.; Fletcher, M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. *Brain Behav. Immun.* **2010**, *24*, 1209–1217. [\[CrossRef\]](#)
24. Torres-Harding, S.; Sorenson, M.; Jason, L.A.; Maher, K.; Fletcher, M.A. Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS). *Bull. IACFS ME* **2008**, *16*, 19–33. [\[PubMed\]](#)

25. Okada, T.; Tanaka, M.; Kuratsune, H.; Watanabe, Y.; Sadato, N. Mechanisms underlying fatigue: A voxel-based morphometric study of chronic fatigue syndrome. *BMC Neurol.* **2004**, *4*, 14. [CrossRef]
26. Barnden, L.R.; Crouch, B.; Kwiatek, R.; Burnet, R.; Mernone, A.; Chryssidis, S.; Scroop, G.; Del Fante, P. A brain MRI study of chronic fatigue syndrome: Evidence of brainstem dysfunction and altered homeostasis. *NMR Biomed.* **2011**, *24*, 1302–1312. [CrossRef]
27. Costa, D.C.; Tannock, C.; Brostoff, J. Brainstem perfusion is impaired in chronic fatigue syndrome. *QJM* **1995**, *88*, 767–773.
28. Cook, D.B.; O'Connor, P.J.; Lange, G.; Steffener, J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. *Neuroimage* **2007**, *36*, 108–122. [CrossRef]
29. Flor-Henry, P.; Lind, J.C.; Koles, Z.J. EEG source analysis of chronic fatigue syndrome. *Psychiatry Res.* **2010**, *181*, 155–164. [CrossRef] [PubMed]
30. Thoma, M.; Froehlich, L.; Hattesoehl, D.B.R.; Quante, S.; Jason, L.A.; Scheibenbogen, C. Why the Psychosomatic View on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Inconsistent with Current Evidence and Harmful to Patients. *Medicina* **2023**, *60*, 83. [CrossRef]
31. Jason, L.A.; Cotler, J.; Islam, M.F.; Sunnquist, M.; Katz, B.Z. Risks for Developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in College Students Following Infectious Mononucleosis: A Prospective Cohort Study. *Clin. Infect. Dis.* **2021**, *73*, e3740–e3746. [CrossRef]
32. König, R.S.; Paris, D.H.; Sollberger, M.; Tschopp, R. Identifying the mental health burden in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients in Switzerland: A pilot study. *Heliyon* **2024**, *10*, e27031. [CrossRef] [PubMed] [PubMed Central]
33. Centers for Disease Control and Prevention. Resources for Medical Students. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Available online: <https://www.cdc.gov/me-cfs/hcp/toolkit/resources-for-medical-students.html> (accessed on 31 July 2025).
34. Bae, J.; Lin, J.S. Healthcare Utilization in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Analysis of US Ambulatory Healthcare Data, 2000–2009. *Front. Pediatr.* **2019**, *7*, 185. [CrossRef] [PubMed] [PubMed Central]
35. Centers for Disease Control and Prevention. ME/CFS Basics. Available online: <https://www.cdc.gov/me-cfs/about/index.html> (accessed on 31 July 2025).
36. Sanal-Hayes, N.E.M.; McLaughlin, M.; Hayes, L.D.; Mair, J.L.; Ormerod, J.; Carless, D.; Hilliard, N.; Meach, R.; Ingram, J.; Sculthorpe, N.F. A scoping review of ‘Pacing’ for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Lessons learned for the long COVID pandemic. *J. Transl. Med.* **2023**, *21*, 720. [CrossRef] [PubMed]
37. Visible. Available online: <https://www.makevisible.com/> (accessed on 1 June 2025).
38. Calm. Available online: <https://www.calm.com/> (accessed on 1 June 2025).
39. Headspace. Available online: <https://www.headspace.com/> (accessed on 1 June 2025).
40. Walitt, B.; Singh, K.; LaMunion, S.R.; Hallett, M.; Jacobson, S.; Chen, K.; Enose-Akahata, Y.; Apps, R.; Barb, J.J.; Bedard, P.; et al. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. *Nat. Commun.* **2024**, *15*, 907. [CrossRef]
41. Eaton-Fitch, N.; Rudd, P.; Er, T.; Hool, L.; Herrero, L.; Marshall-Gradisnik, S. Immune exhaustion in ME/CFS and long COVID. *JCI Insight* **2024**, *9*, e183810. [CrossRef]
42. National Institutes of Health (NIH). Lesser Studied Pathologies—ME/CFS Research Roadmap Working Group. Available online: <https://www.ninds.nih.gov/news-events/events/mecfs-research-roadmap-webinar-series-lesser-studied-pathologies> (accessed on 1 June 2025).
43. Xiong, R.; Gunter, C.; Fleming, E.; Vernon, S.D.; Bateman, L.; Unutmaz, D.; Oh, J. Multi-‘omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients. *Cell Host Microbe* **2023**, *31*, 273–287.e5. [CrossRef]
44. Maksud, R.; Magawa, C.; Eaton-Fitch, N.; Thapaliya, K.; Marshall-Gradisnik, S. Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A systematic review. *BMC Med.* **2023**, *21*, 189. [CrossRef]
45. Hakim, A.; De Wandele, I.; O’Callaghan, C.; Pocinki, A.; Rowe, P. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type. *Am. J. Med. Genet. C. Semin. Med. Genet.* **2017**, *175*, 175–180. [CrossRef]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.